Molecular Measurable Residual Disease (MRD) Clearance (1%) Is Associated with Improved Clinical Outcomes in Patients with Higher-Risk Myelodysplastic Neoplasms (HR-MDS): An Exploratory Analysis of Stimulus-MDS1 in Patients Receiving Sabatolimab or Placebo plus Hypomethylating Agent (HMA)